Precisemab
PrivateLast Round
Seed
Jul 29, 2022
Total Funding Raised
$1.67M
Company Overview
Precisemab is a biotechnology company that develops a proprietary Universal Antibody Lock platform intended to reduce the side effects of antibody drugs by making them active only in diseased areas.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Precisemab Comps
Public and private peers based on sector, stage, and business model.
Precisemab Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Jul 29, 2022 | ||||
| Accelerator | Jan 1, 2021 |
Precisemab Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Science and Technology Council | Grant |
| Taiwan Tech Arena | Accelerator |
| Taiwan Phoenix Digital Health International Accelerator | Accelerator |
| Taiwan Germination Program | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 29, 2022
$1.6M round raised
- Jan 1, 2021
Received funding from Taiwan Germination Program and others.
Precisemab Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Precisemab's valuation, stock price, and market status.
